Globe Newswire (Tue, 31-Mar 8:55 AM ET)
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Globe Newswire (Fri, 20-Feb 9:05 AM ET)
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
Globe Newswire (Fri, 6-Feb 9:25 AM ET)
Globe Newswire (Tue, 3-Feb 8:45 AM ET)
Globe Newswire (Tue, 27-Jan 8:45 AM ET)
Market Chameleon (Wed, 29-Oct 5:53 AM ET)
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Ernexa Therapeutics trades on the NASDAQ stock market under the symbol ERNA.
As of April 6, 2026, ERNA stock price climbed to $0.21 with 363,549 million shares trading.
ERNA has a beta of 1.65, meaning it tends to be more sensitive to market movements. ERNA has a correlation of 0.05 to the broad based SPY ETF.
ERNA has a market cap of $6.11 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ERNA traded as high as $56.25 and as low as $.18.
The top ETF exchange traded funds that ERNA belongs to (by Net Assets): VXF.
ERNA has underperformed the market in the last year with a price return of -92.6% while the SPY ETF gained +31.9%. ERNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -83.5% and -10.8%, respectively, while the SPY returned -4.5% and +0.5%, respectively.
ERNA support price is $.19 and resistance is $.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ERNA shares will trade within this expected range on the day.
